tiprankstipranks
Innovent Biologics Reports H1 2024 Financials
Company Announcements

Innovent Biologics Reports H1 2024 Financials

Innovent Biologics (HK:1801) has released an update.

Pick the best stocks and maximize your portfolio:

Innovent Biologics has announced its unaudited interim financial results for the first half of 2024, revealing a significant increase in revenue from contracts with customers, which rose to RMB 3.95 billion from RMB 2.70 billion in the same period last year. Despite higher revenues, the company reported a larger loss before tax of RMB 392.59 million, compared to a loss of RMB 256.11 million in the first half of 2023. The report indicates that increased investment in research and development, as well as higher selling and marketing expenses, have contributed to the company’s financial performance during this period.

For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyInnovent Biologics: China’s NMPA approves NDA for Dovbleron
TipRanks HongKong Auto-Generated NewsdeskInnovent Biologics Expands Portfolio with New Drug Approval
TipRanks HongKong Auto-Generated NewsdeskInnovent Biologics Incentivizes Employees with Share Options
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App